Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial

被引：0

作者：

Li Zhang

Xin Mei

Zhigang Hu

Bo Yu

Chaoyang Zhang

Yong Li

Kaitai Liu

Xuejun Ma

Jinli Ma

Xingxing Chen

Jin Meng

Wei Shi

Xiaofang Wang

Miao Mo

Zhimin Shao

Zhen Zhang

Xiaoli Yu

Xiaomao Guo

Zhaozhi Yang

机构：

[1] Fudan University Shanghai Cancer Center,Department of Radiation Oncology

[2] Fudan University,Department of Oncology, Shanghai Medical College

[3] Shanghai Key Laboratory of Radiation Oncology,Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine

[4] University of Science and Technology of China,Department of Radiotherapy

[5] the Affiliated Jiangyin Hospital of Nantong University,Department of Radiation Oncology

[6] The First Hospital of Quanzhou Affiliated to Fujian Medical University,Department of Oncology

[7] Guizhou Provincial People’s Hospital,Department of Radiation Oncology

[8] The Affiliated Lihuili Hospital of Ningbo University,Department of Cancer Prevention & Clinical Statistics Center

[9] Fudan University Shanghai Cancer Center,Department of Breast Surgery

[10] Fudan University Shanghai Cancer Center,Key Laboratory of Breast Cancer in Shanghai

[11] Fudan University Shanghai Cancer Center,Department of Medical Oncology

[12] Kashgar Prefecture Second People ’ s Hospital,undefined

[13] Xinjiang Uyghur Autonomous Region,undefined

来源：

BMC Cancer | / 24卷

关键词：

Breast cancer; Supraclavicular nodal irradiation; Target volume; Survival outcome; Toxicity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement
Faneyte, IF
Peterse, JL
van Tinteren, H
Pronk, C
de Vries, EGE
Rodenhuis, S
van de Vijver, MJ
CLINICAL CANCER RESEARCH, 2004, 10 (13) : 4457 - 4463
[32] Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Li, Junjie
Yu, Keda
Pang, Da
Wang, Changqin
Jiang, Jun
Yang, Suisheng
Liu, Yunjiang
Fu, Peifen
Sheng, Yuan
Zhang, Guojun
Cao, Yali
He, Qi
Cui, Shude
Wang, Xijing
Ren, Guosheng
Li, Xinzheng
Yu, Shiyou
Liu, Pengxi
Qu, Xiang
Tang, Jinhai
Wang, Ouchen
Fan, Zhimin
Jiang, Guoqin
Zhang, Jin
Wang, Jiandong
Zhang, Hongwei
Wang, Shui
Zhang, Jianguo
Jin, Feng
Rao, Nanyan
Ma, Binlin
He, Pingqing
Xu, Binghe
Zhuang, Zhigang
Wang, Jianfeng
Sun, Qiang
Guo, Xiaofeng
Mo, Miao
Shao, Zhimin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1774 - +
[33] Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
Iwase, Takuji
Saji, Shigehira
Iijima, Kotaro
Higaki, Kenji
Ohtani, Shoichiro
Sato, Yasuyuki
Hozumi, Yasuo
Hasegawa, Yoshie
Yanagita, Yasuhiro
Takei, Hiroyuki
Tanaka, Maki
Masuoka, Hideji
Tanabe, Masahiko
Egawa, Chiyomi
Komoike, Yoshifumi
Nakamura, Toshitaka
Ohtsu, Hiroshi
Mukai, Hirofumi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3329 - +
[34] Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial
Ma, T.
Wen, L.
Zhang, J.
Zhang, Z.
Zeng, Y.
Wang, Y.
Zheng, J.
Liang, T.
ANNALS OF ONCOLOGY, 2024, 35 : S1494 - S1494
[35] Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni, Marco
Luo, Weixiu
Karlsson, Per
Chirgwin, Jacquie
Aebi, Stefan
Jerusalem, Guy
Neven, Patrick
Hitre, Erika
Graas, Marie-Pascale
Simoncini, Edda
Kamby, Claus
Thompson, Alastair
Loibl, Sibylle
Gavila, Joaquin
Kuroi, Katsumasa
Marth, Christian
Mueller, Bettina
O'Reilly, Seamus
Di Lauro, Vincenzo
Gombos, Andrea
Ruhstaller, Thomas
Burstein, Harold
Ribi, Karin
Bernhard, Jurg
Viale, Giuseppe
Maibach, Rudolf
Rabaglio-Poretti, Manuela
Gelber, Richard D.
Coates, Alan S.
Di Leo, Angelo
Regan, Meredith M.
Goldhirsch, Aron
LANCET ONCOLOGY, 2018, 19 (01): : 127 - 138
[36] German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer
von Minckwitz, Gunter
Moebus, Volker
Schneeweiss, Andreas
Huober, Jens
Thomssen, Christoph
Untch, Michael
Jackisch, Christian
Diel, Ingo J.
Elling, Dirk
Conrad, Bettina
Kreienberg, Rolf
Mueller, Volkmar
Lueck, Hans-Joachim
Bauerfeind, Ingo
Clemens, Michael
Schmidt, Marcus
Noeding, Stefanie
Forstbauer, Helmut
Barinoff, Jana
Belau, Antje
Nekljudova, Valentina
Harbeck, Nadia
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) : 3531 - 3539
[37] Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial
Amelie de Gregorio
Lothar Häberle
Peter A. Fasching
Volkmar Müller
Iris Schrader
Ralf Lorenz
Helmut Forstbauer
Thomas W. P. Friedl
Emanuel Bauer
Nikolaus de Gregorio
Miriam Deniz
Visnja Fink
Inga Bekes
Ulrich Andergassen
Andreas Schneeweiss
Hans Tesch
Sven Mahner
Sara Y. Brucker
Jens-Uwe Blohmer
Tanja N. Fehm
Georg Heinrich
Krisztian Lato
Matthias W. Beckmann
Brigitte Rack
Wolfgang Janni
Breast Cancer Research, 22
[38] Sparing Irradiation vs. Conventional Irradiation to the Medial Retropharyngeal Space in Patients with Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Multicenter, Randomized Phase III Trial
Mao, Y. P.
Wang, S. X.
Gao, T.
Zhang, N.
Liang, X. Y.
Tang, L.
Zhou, G. Q.
Guo, R.
Zhang, Y.
Chen, L.
Luo, W. J.
Li, Y.
Liang, S.
Lin, L.
Li, W. F.
Liu, X.
Xu, C.
Lv, J. W.
Liu, L. Z.
Li, J. B.
Xie, F. Y.
Sun, Y.
Ma, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S97 - S97
[39] Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
Del Mastro, Lucia
Mansutti, Mauro
Bisagni, Giancarlo
Ponzone, Riccardo
Durando, Antonio
Amaducci, Laura
Campadelli, Enrico
Cognetti, Francesco
Frassoldati, Antonio
Michelotti, Andrea
Mura, Silvia
Urracci, Ylenia
Sanna, Giovanni
Gori, Stefania
De Placido, Sabino
Garrone, Ornella
Fabi, Alessandra
Barone, Carla
Tamberi, Stefano
Bighin, Claudia
Puglisi, Fabio
Moretti, Gabriella
Arpino, Grazia
Ballestrero, Alberto
Poggio, Francesca
Lambertini, Matteo
Montemurro, Filippo
Bruzzi, Paolo
LANCET ONCOLOGY, 2021, 22 (10): : 1458 - 1467
[40] Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible -: results of a randomized, open-label Phase II study
Wildiers, H.
Dirix, L.
Neven, P.
Prove, A.
Clement, P.
Amant, F.
Paridaens, R.
EJC SUPPLEMENTS, 2007, 5 (04): : 208 - 208

← 1 2 3 4 5 →